Suppresses PAF-induced bronchoconstriction in the guinea pig (ED50=0.9 mg/kg orally).
Product Details
| Formula: | C27H30N4O |
| |
| MW: | 426.6 |
| |
| CAS: | 60607-34-3 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in ethanol or DMSO. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action: F. P. Nijkamp, et al.; Naunyn-Schmeideberg's Arch. Pharmacol.
340, 111 (1989),
Abstract;
Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats: K. Ohmori, et al.; Arch. Int. Pharmacodyn. Ther.
275, 139 (1985),
Abstract;
Oxatomide inhibits the release of bronchoconstrictor arachidonic acid metabolites (iLTC4 and PGD2) from rat mast cells and guinea-pig lung: Y. Kosaka, et al.; Agents Actions
21, 32 (1985),
Abstract;
Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy: D. M. Richards, et al.; Drugs
27, 210 (1984),
Abstract;
